Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

White House to finish allocating 80 million U.S.-made COVID-19 shots for shipment abroad

Published 06/17/2021, 12:44 PM
Updated 06/17/2021, 11:25 PM
© Reuters. FILE PHOTO: Vials labelled "Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine" are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic/File Photo

By Carl O'Donnell and Michael Erman

(Reuters) -The White House will finish allocating 80 million U.S.-made COVID-19 shots that it has pledged to ship abroad in the coming days, with shipments going out as soon as the countries are ready to receive them, a top U.S. official said on Thursday.

The United States has already begun shipping doses, said White House COVID-19 response coordinator Jeff Zients, adding that some shots were meant to go to Canada on Thursday and some will go to Brazil in the coming weeks.

Canada said it expected to receive about one million Moderna (NASDAQ:MRNA) Inc shots from the United States on Thursday. Later, U.S. Secretary of State Antony Blinken said on Twitter that the United States had delivered a million doses to Canada.

The Biden administration earlier this month announced plans for how it will allocate 25 million shots and said it would allocate the remaining 55 million shots by the end of June.

The United States has been increasing shot shipments abroad as it progresses quickly in its vaccination campaign for its own residents. The White House announced last week that it was purchasing 500 million Pfizer Inc (NYSE:PFE) shots to donate to poorer countries in 2021 and 2022.

More than 175 million Americans have received at least one COVID-19 vaccine dose so far, and nearly 65% of U.S. adults have received one shot. Meanwhile, countries such as India and Brazil have continued to face severe outbreaks of COVID-19 and are still in desperate need of shots.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zients said U.S. cases and deaths are down more than 90% since late January and are at their lowest level since the start of the pandemic.

But he cautioned he is concerned about low vaccination rates in some U.S. communities, especially as a dangerous new variant first identified in India, known as the Delta variant, is spreading in the United States.

Rochelle Walensky, the director of the U.S. Centers for Disease Control and Prevention (CDC), said her agency will present details on Friday about more than 300 confirmed cases of heart inflammation reported among the more than 20 million young adults and adolescents who have received COVID-19 vaccines.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.